Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2

Conditions

Mesothelioma 2Pancreatic Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Pemetrexed 12Cisplatin 11pembrolizumab 8Carboplatin 6Ipilimumab 5Nivolumab 4LMB-100 4durvalumab 3Gemcitabine 3tremelimumab 2tazemetostat 2anetumab ravtansine 2Vinorelbine 2Plicamycin 2Dexamethasone 2Cyclophosphamide 2Bevacizumab 2vandetanib 1tocilizumab 1spartalizumab 1ribociclib 1rebastinib 1pevonedistat 1olaparib 1niraparib 1nintedanib 1fludarabine phosphate 1fludarabine 1epacadostat 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Mesothelioma × anetumab ravtansine × Clear all
NCT03926143 2023-08-04

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

Bayer

Phase 2 Terminated
9 enrolled 10 charts
Other solid neoplasmThoracic

Mesothelioma

NCT02610140 2020-11-04

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

Bayer

Phase 2 Completed
248 enrolled 23 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡